Global Intravenous Immunoglobulin Market Expected to Reach USD 12,632 Million

The global intravenous immunoglobulin market accounted for USD 7861 million in 2015 and is projected to reach USD 12,632 million by 2022, registering a CAGR of 7.1 percent from 2016 to 2022. North America and Asia-Pacific collectively occupy almost three-fourth of the global market revenue. Immunoglobulin (IG) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to IG, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) is used in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology.

The prevalence of a host of antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness toward antibody deficiency, and rare immune disorders among patient population drive the growth of the global IVIG market. However, stringent government regulations towards immunoglobulin products and high risk of side effects owing to the use of intravenous immunoglobulin are expected to hamper the growth of the market.

Based on application segment, hypogammaglobulinemia held the largest market share in 2015 and is anticipated to continue this trend in near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment. In 2015, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the IVIG market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and coupled by the presence of large plasma production facilities.

The key companies profiled in the report include Baxter International Inc; CSL Ltd., Grifols, S.A.; Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc.; Shire (Baxalta); and Bayer AG. Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc. – Allied Market Research